{{Rsnum
|rsid=733722
|Gene=CHAT
|Chromosome=10
|position=50816943
|Orientation=plus
|GMAF=0.2746
|Gene_s=CHAT,SLC18A3
|Assembly=GRCh37.p2
|GenomeBuild=37.2
|dbSNPBuild=134
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 58.4 | 37.2 | 4.4
| HCB | 33.6 | 44.5 | 21.9
| JPT | 38.9 | 46.0 | 15.0
| YRI | 73.5 | 23.1 | 3.4
| ASW | 68.4 | 28.1 | 3.5
| CHB | 33.6 | 44.5 | 21.9
| CHD | 24.8 | 56.9 | 18.3
| GIH | 52.5 | 40.6 | 6.9
| LWK | 67.3 | 29.1 | 3.6
| MEX | 31.0 | 46.6 | 22.4
| MKK | 66.7 | 30.8 | 2.6
| TSI | 63.7 | 29.4 | 6.9
| HapMapRevision=28
}}[[rs733722]], also known as -5293C>T, is a SNP near the choline acetyltransferase [[CHAT]] gene. 

A study of 121 [[Alzheimer's disease]] patients treated primarily with the acetylcholinesterase (AChE) inhibitors [[donepezil]] or [[galantamine]] found different rates of mental decline depending on [[rs733722]] genotypes. Individuals of [[rs733722]](C;C) genotype effectively showed declines in cognition over time equivalent to untreated patients, whereas [[rs733722]](C;T) individuals showed less decline, and [[rs733722]](T;T) patients had a negligible decline over the course of the study (~15 months).{{PMID|16424819}}

An earlier study by these authors found no association between SNPs in this gene and actual risk for Alzheimer's.{{PMID|12759818}}

{{PMID Auto
|PMID=18072279
|Title=Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA.
|OA=1
}}

{{PMID Auto
|PMID=18165968
|Title=Identification of pharmacogenetic markers in smoking cessation therapy.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}